Knightscope Partners with U.S. Air Force on Autonomous Security Robots
The U.S. Air Force Research Laboratory and AFWERX have streamlined the SBIR program to accelerate the adoption of innovative solutions. This award underscores the Air Force's commitment to integrating advanced technologies like Knightscope's ASRs, which combine machine learning, autonomous navigation, and sensor driven anomaly detection to provide unmatched situational awareness while enhancing operational efficiency.
"Knightscope is honored to collaborate with the U.S. Air Force in shaping the future of national security," said William Santana Li, Chairman and CEO, Knightscope. "This initial SBIR award marks the beginning of our expanded focus on the federal public sector and highlights the transformative potential of our technology to make America safer and stronger."
Under the Air Force contract, Knightscope will evaluate current Air Force security protocols and recommend ways to deploy ASRs to counter emerging threats. This initiative lays the foundation for future Knightscope technology pilots across the U.S. military, federal law enforcement, and civilian agencies, while advancing the Department of the Air Force's mission to safeguard America and its critical infrastructure.
Knightscope recently announced an upgrade to its K5 Autonomous Security Robot (ASR) through cutting-edge advancements in machine learning and sensor fusion. The upgraded K5, now smarter, and more capable, can patrol vast and more complex environments — from sprawling parking lots and logistics hubs to military bases and beyond. With enhanced autonomous navigation, this evolution signals the start of a new era if remotely monitored large-scale security operations nationwide.
About AFRL and AFWERX
The Air Force Research Laboratory (AFRL) leads the discovery and development of technologies critical to the U.S. Air Force (USAF). AFWERX, its innovation arm, brings American ingenuity from small businesses to the Department of the Air Force, enabling rapid technology transitions to operational capabilities. For more, visit afresearchlab.com and afwerx.com.
Experience the Future Today
Knightscope's portfolio of advanced public safety technologies – including the K1 Laser, Blue Light Emergency Communication Devices, Autonomous Security Robots and Automated Gunshot Detection Services – can enhance security where it matters most, book a discovery call today at www.knightscope.com/discover.
About Knightscope
Knightscope is transforming public safety with cutting-edge robotics and AI technologies. From autonomous security robots to advanced detection systems, Knightscope is committed to building safer communities where you live, work, study and visit. Our long-term ambition is bold but simple: to make the United States of America the safest country in the world. Learn more about us at www.knightscope.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements can be identified by the use of words such as "should," "may," "intends," "anticipates," "believes," "estimates," "projects," "forecasts," "expects," "plans," "proposes" and similar expressions. Forward-looking statements contained in this press release and other communications include, but are not limited to, statements about the Company's goals, profitability, growth, prospects, reduction of expenses, and outlook. Although Knightscope believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks, uncertainties and other important factors that could cause actual results to differ materially from such forward-looking statements, including the factors discussed under the heading "Risk Factors" in Knightscope's Annual Report on Form 10-K for the year ended December 31, 2023, as updated by its other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date of the document in which they are contained, and Knightscope does not undertake any duty to update any forward-looking statements, except as may be required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250128604994/en/
Contacts
Public Relations: Drew McDowell press@yourwashingtonoffice.com Knightscope, Inc. (650) 924-1025 ext. 6
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Rezolve AI (RZLV) Launches Global Professional Services Division for AI Growth
Rezolve AI PLC (NASDAQ:RZLV) is one of the most popular AI penny stocks to buy according to billionaires. On June 26, the company announced the creation of Rezolve Ai Professional Services, a global growth platform to meet rising demand in the enterprise AI services market. Source: unsplash The company appointed Sauvik Banerjjee to lead the division's efforts. Banerjjee, formerly the Global Commerce Head at Accenture and a founder and CTO at Tata Digital, is now the President of Rezolve Ai Global Professional Services and Chief Digital Officer. The new division will provide a range of services designed to help enterprises effectively integrate and utilize Rezolve's 'Brain Suite' AI technology. These services include C-suite advisory on AI roadmaps, data and architecture readiness assessments, tailored 'Brain Suite' model training and integration, as well as change management and continuous optimization. The creation of this division follows Rezolve's achievement of $70 million in Annual Recurring Revenue (ARR) ahead of schedule, with expectations to exceed $100 million ARR by the end of 2025. The company's platform currently supports over 50 enterprise customers and engages 16.5 million monthly active users across 42 million devices. Rezolve AI PLC (NASDAQ:RZLV) provides generative AI solutions specifically designed for the retail and e-commerce sectors. Its platform enables real-time consumer engagement across millions of devices, powering dynamic search, personalized promotions, and transactional experiences. While we acknowledge the potential of RZLV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Defensive Stocks to Buy in a Volatile Market. Disclosure: None. This article is originally published at Insider Monkey. Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
an hour ago
- Yahoo
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Canopy Growth seems unable to overcome the industrywide challenges it faces. Novavax's recent quarterly update, though strong, says little about its prospects. 10 stocks we like better than Canopy Growth › Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so. You should be careful to avoid catching falling knives. Let's consider two stocks that have significantly lagged the market in recent years but could still fall further: Canopy Growth (NASDAQ: CGC) and Novavax (NASDAQ: NVAX). Canopy Growth emerged as a leader in the cannabis industry toward the end of the past decade. The company has significant operations in Canada, the U.S., and various countries worldwide, including Germany. Despite its position in these markets, Canopy Growth has been a profoundly disappointing investment over the past five years. Its latest results provided another example as to why. During the fourth quarter of its fiscal 2025, which ended March 31, Canopy Growth's net revenue declined by 11% year over year to 65 million Canadian dollars ($47.6 million). The company's loss per share for the period was CA$1.43 ($1.05), worse than the CA$1.03 ($0.75) it reported in the prior-year quarter. In fairness, Canopy Growth's troubles aren't entirely its fault. The cannabis industry has been a mess due to legal and regulatory challenges; competition from illicit channels, sometimes even where the product is legal; and oversupply, particularly in Canada, which legalized recreational use of cannabis for adults in 2018. Hardly any pot company has found consistent success over the past five years, despite different focuses, strategies, and executions across the industry. That may suggest the problem is not exclusive to specific companies. No matter whose fault it is, though, Canopy Growth's business is in shambles, and things are not about to get better. True, the company is engaged in cost-cutting efforts while refocusing its portfolio in Canada on in-demand items, such as vapes and pre-rolls. Management predicts that it will achieve positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) in "the near-term." Yet, even if Canopy Growth gets there, positive EBITDA would only be a step toward profitability. The company's efforts to reduce expenses may help boost margins in the short term. But it's challenging to envision a path for it to perform well in the long run, given the industry challenges that have led to inconsistent financial results over the past half-decade. Are investors to believe that, after all this time and countless failures across the industry -- both those of Canopy Growth and of others -- the company has finally cracked the code? Convincing the market that that's the case will require more than just positive adjusted EBITDA. I see little reason to expect the pot grower to perform well over the next five years. In fact, I'd expect the stock to sink even further -- and advise investors to stay far away. Examining Novavax's financial results and recent progress may suggest that the stock is a compelling investment opportunity. In the first quarter, the company's revenue was $666.7 million, compared to just $93.9 million for the comparable period of the previous fiscal year. Net income was $518.6 million, compared to a net loss of $147.6 million in the first quarter of 2024. Furthermore, Novavax recently reported positive results from phase 3 studies for its stand-alone influenza vaccine and combination COVID-19/flu vaccine. That's to say nothing of the partnerships it's signed with companies like Sanofi and Takeda Pharmaceuticals, which have paid Novavax for the rights to its COVID vaccines in various countries. But can the company sustain its performance over the long run? Probably not, and here's why. First, the coronavirus vaccine market has been inconsistent and hard to predict. Recent regulatory guidance in the U.S. may further complicate matters, with the Department of Health and Human Services no longer recommending the vaccine for certain populations, including pregnant women and healthy children. It's also worth noting that Novavax has generally played second fiddle to the leaders in this space, Moderna and Pfizer. Novavax's strong financial results in the first quarter are not at all indicative of how it will perform year in and year out. Second, the company's phase 3 wins for its two leading vaccines were not significant achievements. Although they induced strong immune responses in participants, Novavax itself states that these trials were not designed to demonstrate statistical significance. In other words, these results won't support approval. And while they're a good stepping stone to phase 3 studies that would, Novavax is waiting for a partner with big pockets to run these trials. That means it either doesn't have the funds to go at it alone, or management doesn't think doing so without a partner will be worth the investment -- or both. Even if it does find a partner, other companies (including Moderna) have made significant strides in developing competing vaccines. Lastly, the infusion of cash it received from its partnership with Sanofi will eventually run out. The company's business will likely have little to show for itself after that point. All these factors make Novavax unattractive to long-term investors, as the stock could fall much further than it has in the past five years. Before you buy stock in Canopy Growth, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Canopy Growth wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $694,758!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $998,376!* Now, it's worth noting Stock Advisor's total average return is 1,058% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. 2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet was originally published by The Motley Fool
Yahoo
an hour ago
- Yahoo
5 No-Brainer Artificial Intelligence (AI) Stocks to Buy on the Dip
The stocks on this list have performed well since the AI boom started in 2023. Their underlying businesses are poised to grow for years to come. Investors should view share price declines as opportunities to buy and hold for the next five years or longer. 10 stocks we like better than Palantir Technologies › It's probably safe to say that artificial intelligence (AI) is here to stay. Investments in AI infrastructure continue to soar, and companies are racing to develop and implement AI in nearly every facet of their business models. Researchers believe that over time, artificial intelligence will impact many of the world's jobs and create trillions of dollars in economic growth. Some of the top AI stocks have already generated impressive returns for investors since the AI market rally began in 2023. However, given the long-term growth likely ahead, it would be wise to view price declines as opportunities to buy into companies leading the AI wave. Here are five no-brainer AI winners that investors should buy on the dip and hold for the next five years and beyond. AI is ultimately software, and Palantir Technologies (NASDAQ: PLTR) is among the best at helping its government and corporate customers wield AI's potential. Palantir develops custom AI software on its proprietary platforms, which can perform a range of tasks, from identifying fraud to optimizing supply chains to supporting military missions. Palantir's revenue growth has continued to accelerate since last summer, following the launch of its Artificial Intelligence Platform (AIP). Almost any company large enough to invest in AI software is a potential Palantir client. There are over 20,000 large companies in the United States alone, and Palantir still has just 622 commercial customers. The stock's valuation is extremely rich at the moment, making it an obvious candidate to revisit when the price drops. On the hardware side of AI are semiconductors (chips), also known as the building blocks of technology. Arm Holdings (NASDAQ: ARM) designs proprietary processing chip architectures and generates revenue from licensing fees and royalties. Arm's customers include the leading AI chip companies, such as Nvidia. To date, customers have shipped over 310 billion Arm-based chips, and Arm continues to increase its market share. Arm is highly profitable, as it has almost zero expenses outside of research and development. Global chip demand is increasing over time as AI, cloud computing, autonomous vehicles, and other emerging technologies require more processing power. Analysts estimate that Arm will grow earnings by an average of 22% annually over the long term, an impressive pace. However, its steep forward price-to-earnings (P/E) ratio of 85 means investors should probably wait to buy for now. Electronics giant Apple (NASDAQ: AAPL) has a massive AI opportunity in front of it. The company's iOS ecosystem boasts over 2.3 billion active users across smartphones, computers, and wearable devices. Unfortunately, Apple has gotten off to a slow start with AI, reportedly going back to the drawing board to fix its Siri voice assistant product. Despite the struggles, Apple likely has time to figure things out thanks to its famously sticky ecosystem. In the meantime, Apple is still poised to enjoy double-digit annualized earnings growth, partly due to its massive stock buyback programs, which steadily reduce the share count and increase earnings per share. There's a reason it's one of Warren Buffett's favorite stocks. Apple stock still has long-term upside, but it would be best to buy once its valuation falls from its current P/E ratio of 30 times 2025 earnings estimates. Social media juggernaut Meta Platforms (NASDAQ: META) is leveraging AI in many ways. It developed and open-sourced its Llama AI model, accumulating over 1.2 billion downloads. It is also building a consumer ecosystem with Meta-branded headsets and smart glasses, an effort to break free from the control that smartphone makers have had over its apps. AI is also helping to enhance Meta's core business, which is advertising to the 3.4 billion people using its apps each day. Meta has integrated AI into its ads business to increase monetization. Eventually, AI could automate ads, likely boosting profit margins for a company that was exceptionally lucrative to begin with. The stock's P/E ratio (28) has drifted higher since 2023, but anticipated mid-teens annualized earnings growth makes Meta a table-pounding buy on pullbacks. Semiconductor giant Broadcom (NASDAQ: AVGO) is experiencing increased growth due to surging demand for its AI networking chips, as well as its custom accelerator chips (XPUs). The company's AI-related semiconductor revenue grew by 46% year over year in the second quarter of 2025 and could add billions of dollars in incremental revenue over the coming years. Investors may also like that Broadcom isn't a pure AI investment. Infrastructure software for enterprises has become a significant portion of Broadcom's business, accounting for approximately 40% of its revenue. Additionally, the stock offers a rising dividend that management has increased for 15 consecutive years. Analysts anticipate 25% annualized earnings growth over the next three to five years, making Broadcom a solid buy at 41 times 2025 earnings estimates and a no-brainer if the stock drops further. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $674,432!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,005,854!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to Meta Platforms CEO Mark Zuckerberg, is a member of The Motley Fool's board of directors. Justin Pope has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Apple, Meta Platforms, Nvidia, and Palantir Technologies. The Motley Fool recommends Broadcom. The Motley Fool has a disclosure policy. 5 No-Brainer Artificial Intelligence (AI) Stocks to Buy on the Dip was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
